20 January 2016

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that it will host a capital markets event on the afternoon of Tuesday 26 January 2016.

The event, for equity analysts and institutional investors, will include technical and commercial presentations to provide greater detail on the exciting progress across the Company's portfolio of products.

The event will be webcast for private and other shareholders. To access the webcast live, please log on to the following web address approximately 5 minutes before 3.15pm GMT on the day of the event:

http://vm.buchanan.uk.com/2016/futuramedical260116/registration.htm

A recording of the webcast will be made available for several days from 27 January 2016 at www.futuramedical.com and at www.buchanan.uk.com.

The event will start at 3.15pm with an introduction by James Barder, Futura's Chief Executive, and then comprise technical and commercial presentations on the Company's product pipeline beginning with CSD500, Futura's erectogenic condom.

The CSD500 presentations will be followed by details of the clinical trial and US market opportunity for MED2002, Futura's novel gel for erectile dysfunction, and then by presentations on the Company's pain relief portfolio, TPR100 and TIB200.

Analysts and investors who would like to attend the capital markets event, please contact Buchanan at the details below.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com